Abstract:Patients with chronic pain often develop comorbid depressive symptoms, which makes the pain symptoms more complicated and refractory. However, the underlying mechanisms are poorly known. Here, in a repeated complete Freund's adjuvant (CFA) male mouse model, we reported a specific regulatory role of the paraventricular thalamic nucleus (PVT) glutamatergic neurons, particularly the anterior PVT (PVA) neurons, in mediating chronic pain and depression comorbidity (CDC). Our c-Fos protein staining observed increased PVA neuronal activity in CFA-CDC mice. In wild-type mice, chemogenetic activation of PVA glutamatergic neurons was sufficient to decrease the 50% paw withdrawal thresholds (50% PWTs), while depressive-like behaviors evaluated with immobile time in tail suspension test (TST) and forced swim test (FST) could only be achieved by repeated chemogenetic activation. Chemogenetic inhibition of PVA glutamatergic neurons reversed the decreased 50% PWTs in CFA mice without depressive-like symptoms and the increased TST and FST immobility in CFA-CDC mice. Surprisingly, in CFA-CDC mice, chemogenetically inhibiting PVA glutamatergic neurons failed to reverse the decrease of 50% PWTs which could be restored by rapid-onset antidepressant S-ketamine. Further behavioral tests in chronic restraint stress mice and CFA pain mice indicated that PVA glutamatergic neuron inhibition and S-ketamine independently alleviate sensory and affective pain. Molecular profiling and pharmacological studies revealed the 5-hydroxytryptamine receptor 1D (Htr1d) in CFA pain-related PVT engram neurons as a potential target for treating CDC. These findings identified novel CDC neuronal and molecular mechanisms in the PVT and provided insight into the complicated pain neuropathology under a comorbid state with depression and related drug development. Significance Statement Patients with chronic pain frequently experience concurrent depressive symptoms, which complicates the treatment of the pain symptoms. Recently, the paraventricular thalamic nucleus (PVT) has attracted growing interest in modulating animal behaviors of pain sensation and stress-related affective disorders. However, whether and how PVT mediate chronic pain and depression comorbidity (CDC) remains poorly understood. Here, utilizing chemogenetics, viral labelling, neuronal cell types-based TRAP (translating ribosome affinity purification) technology and pharmacological studies, our current study revealed that PVT is a central hub for regulating sensory pain and depressive-like behaviors but not affective pain by functioning through the 5-hydroxytryptamine receptor 1D (Htr1d). These findings provide new insights of the regulatory role of the PVT and a potential molecular target for future analgesic development.

Scope of Biogeography Based Optimization for Economic Load Dispatch and Multi-Objective Unit Commitment Problem

Correction: Divergent Modulation of Pain and Anxiety by GABAergic Neurons in the Ventrolateral Periaqueductal Gray and Dorsal Raphe.

Transcriptomic and proteomic profiling of the anterior cingulate cortex in neuropathic pain model rats

Transcriptome Analysis of the Mouse Medial Prefrontal Cortex in Chronic Constriction Injury Model: Implications of neuropathic pain-induced cognitive impairment

The cAMP Response Element- Binding Protein/Brain-Derived Neurotrophic Factor Pathway in Anterior Cingulate Cortex Regulates Neuropathic Pain and Anxiodepression Like Behaviors in Rats

Gene Transcript Alterations in the Spinal Cord, Anterior Cingulate Cortex, and Amygdala in Mice Following Peripheral Nerve Injury

A Central Amygdala Input to the Parafascicular Nucleus Controls Comorbid Pain in Depression.

Neuronal and molecular mechanisms underlying chronic pain and depression comorbidity in the paraventricular thalamus

A neural circuit for comorbid depressive symptoms in chronic pain

Study on analgesic effect of Shentong Zhuyu Decoction in neuropathic pain rats by network pharmacology and RNA-Seq

Transcriptome Analysis of the Mouse Medial Prefrontal Cortex in a Chronic Constriction Injury Model

Contribution of AMPA Receptor-Mediated LTD in LA/BLA-CeA Pathway to Comorbid Aversive and Depressive Symptoms in Neuropathic Pain.

Comprehensive Analysis of Differentially Expressed Genes and Key Pathways in Neuropathic Pain by Spinal Nerve Ligation

Molecular mechanisms of NMDA receptor-MAPK-CREB pathway underlying the involvement of the anterior cingulate cortex in pain-related aversion

Contribution of AMPA Receptor-Mediated LTD in LA/BLA-CeA Pathway to Comorbid Aversive and Depressive Symptoms in Neuropathic Pain

Differences in the neural basis and transcriptomic patterns in acute and persistent pain-related anxiety-like behaviors

Alterations of endogenous pain-modulatory system of the cerebral cortex in the neuropathic pain

Helms campaigns here Hearn answers students ' questions

Integration of microbiota and metabolomics reveals the analgesic mechanisms of emodin against neuropathic pain

Neuromolecular and behavioral effects of cannabidiol on depressive-associated behaviors and neuropathic pain conditions in mice

Effect of diethyl pyrocarbonate on the biological activity of intact TMV and TMV-RNA.